HRP20200785T1 - Novi heterociklični spoj - Google Patents
Novi heterociklični spoj Download PDFInfo
- Publication number
- HRP20200785T1 HRP20200785T1 HRP20200785TT HRP20200785T HRP20200785T1 HR P20200785 T1 HRP20200785 T1 HR P20200785T1 HR P20200785T T HRP20200785T T HR P20200785TT HR P20200785 T HRP20200785 T HR P20200785T HR P20200785 T1 HRP20200785 T1 HR P20200785T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxypiperidin
- benzo
- imidazol
- propan
- bromo
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 40
- 239000000126 substance Substances 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 150000002431 hydrogen Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- -1 hydroxyimino Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001246 bromo group Chemical group Br* 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000004758 (C1-C4) alkoxyimino group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 235000019253 formic acid Nutrition 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims 2
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical compound COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 claims 1
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 claims 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 claims 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- XGVBXSFNMYCZHY-SCYXSXAHSA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)(C(F)(F)F)O)C=C1)C Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)(C(F)(F)F)O)C=C1)C XGVBXSFNMYCZHY-SCYXSXAHSA-N 0.000 claims 1
- WPADLMCJIHRONF-HIFRSBDPSA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C WPADLMCJIHRONF-HIFRSBDPSA-N 0.000 claims 1
- CQUMKANTTFCOPU-YPMHNXCESA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C(F)(F)F Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C(F)(F)F CQUMKANTTFCOPU-YPMHNXCESA-N 0.000 claims 1
- ZVXBQEJAGMWZLG-YPMHNXCESA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)Cl Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)Cl ZVXBQEJAGMWZLG-YPMHNXCESA-N 0.000 claims 1
- FWLNWCZUQOTJAK-YPMHNXCESA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)F Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)F FWLNWCZUQOTJAK-YPMHNXCESA-N 0.000 claims 1
- ZLXNDYOSAPYTQR-ICSQTIAXSA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)C Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)C ZLXNDYOSAPYTQR-ICSQTIAXSA-N 0.000 claims 1
- MTBDUVVGJIOXEU-WPLSFSDESA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)C(F)(F)F Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)C(F)(F)F MTBDUVVGJIOXEU-WPLSFSDESA-N 0.000 claims 1
- BDZYOGLBQWDDSP-WPLSFSDESA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)Cl Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)Cl BDZYOGLBQWDDSP-WPLSFSDESA-N 0.000 claims 1
- KCLNOWXPECRLPR-WPLSFSDESA-N BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)F Chemical compound BrC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)F KCLNOWXPECRLPR-WPLSFSDESA-N 0.000 claims 1
- BJHWEMKEFNUGKO-OCCSQVGLSA-N BrC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)C Chemical compound BrC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)C BJHWEMKEFNUGKO-OCCSQVGLSA-N 0.000 claims 1
- YRWDTYHKPOIMCY-AOUZGSJDSA-N BrC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)O)C Chemical compound BrC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)O)C YRWDTYHKPOIMCY-AOUZGSJDSA-N 0.000 claims 1
- PBIJTOODNAECJC-HIFRSBDPSA-N BrC1=C2C=NN(C2=CC=C1C)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC1=C2C=NN(C2=CC=C1C)CC(C[C@H]1NCCC[C@@H]1O)=O PBIJTOODNAECJC-HIFRSBDPSA-N 0.000 claims 1
- SONQDLJRSNTNDP-HIFRSBDPSA-N BrC1=CC2=C(N(C(=N2)CO)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1 Chemical compound BrC1=CC2=C(N(C(=N2)CO)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1 SONQDLJRSNTNDP-HIFRSBDPSA-N 0.000 claims 1
- OERPMYRTRQBROC-HIFRSBDPSA-N BrC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1 Chemical compound BrC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1 OERPMYRTRQBROC-HIFRSBDPSA-N 0.000 claims 1
- IWKLWNGXXCWBLT-HIFRSBDPSA-N BrC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Br Chemical compound BrC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Br IWKLWNGXXCWBLT-HIFRSBDPSA-N 0.000 claims 1
- XDIUFHUZRKOWIL-OLZOCXBDSA-N BrC1=CC=C2C(=N1)N(C=C2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC1=CC=C2C(=N1)N(C=C2)CC(C[C@H]1NCCC[C@@H]1O)=O XDIUFHUZRKOWIL-OLZOCXBDSA-N 0.000 claims 1
- KSMKOQNRJLXLOD-NEPJUHHUSA-N BrC1=CC=C2C(=N1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC1=CC=C2C(=N1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)=O KSMKOQNRJLXLOD-NEPJUHHUSA-N 0.000 claims 1
- DIRBULWDTAHPMF-PWSUYJOCSA-N BrC1=CC=C2C(=N1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC1=CC=C2C(=N1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O DIRBULWDTAHPMF-PWSUYJOCSA-N 0.000 claims 1
- VZSDVCLHONXEJI-SOYIIFOFSA-N BrC=1C(=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)O)C Chemical compound BrC=1C(=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)O)C VZSDVCLHONXEJI-SOYIIFOFSA-N 0.000 claims 1
- VHTFONUOEBXEGQ-JROPRLTOSA-N BrC=1C(=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)O)Cl Chemical compound BrC=1C(=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)O)Cl VHTFONUOEBXEGQ-JROPRLTOSA-N 0.000 claims 1
- CGGPUBASHXWAMW-HIFRSBDPSA-N BrC=1C(=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1)F Chemical compound BrC=1C(=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1)F CGGPUBASHXWAMW-HIFRSBDPSA-N 0.000 claims 1
- HFWQJGLZXXROJT-YPMHNXCESA-N BrC=1C2=C(C=NC=1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC=1C2=C(C=NC=1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O HFWQJGLZXXROJT-YPMHNXCESA-N 0.000 claims 1
- IUZOFBBVTHIFNF-HIFRSBDPSA-N BrC=1C=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1)C Chemical compound BrC=1C=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1)C IUZOFBBVTHIFNF-HIFRSBDPSA-N 0.000 claims 1
- UCTNITGZEUSADA-HIFRSBDPSA-N BrC=1C=C2C(=NC=1)C=CN2CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC=1C=C2C(=NC=1)C=CN2CC(C[C@H]1NCCC[C@@H]1O)=O UCTNITGZEUSADA-HIFRSBDPSA-N 0.000 claims 1
- JKHJTCAVOMGFBS-YPMHNXCESA-N BrC=1C=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC=1C=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)=O JKHJTCAVOMGFBS-YPMHNXCESA-N 0.000 claims 1
- SORGRODLWFFSJT-YPMHNXCESA-N BrC=1C=C2C(=NC=1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=NO Chemical compound BrC=1C=C2C(=NC=1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=NO SORGRODLWFFSJT-YPMHNXCESA-N 0.000 claims 1
- WUFVJBZKAQJOPA-YPMHNXCESA-N BrC=1C=C2C(=NC=1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound BrC=1C=C2C(=NC=1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O WUFVJBZKAQJOPA-YPMHNXCESA-N 0.000 claims 1
- ZLDWBNNSVQZQDC-HIFRSBDPSA-N BrC=1C=CC2=C(N(C(=N2)CO)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1 Chemical compound BrC=1C=CC2=C(N(C(=N2)CO)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1 ZLDWBNNSVQZQDC-HIFRSBDPSA-N 0.000 claims 1
- KRJBABOQXLWLBG-HIFRSBDPSA-N BrC=1C=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1 Chemical compound BrC=1C=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1 KRJBABOQXLWLBG-HIFRSBDPSA-N 0.000 claims 1
- ZTTHLHRYQDKXCB-ZBFHGGJFSA-N CC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)C Chemical compound CC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)C ZTTHLHRYQDKXCB-ZBFHGGJFSA-N 0.000 claims 1
- UCQMKNUVPJVLTA-WBVHZDCISA-N CC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1C Chemical compound CC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1C UCQMKNUVPJVLTA-WBVHZDCISA-N 0.000 claims 1
- NAUDZBJMEJVRAJ-ZBFHGGJFSA-N CON=C(CN1C=NC2=C1C=C(C(=C2)Cl)Cl)C[C@H]1NCCC[C@@H]1O Chemical compound CON=C(CN1C=NC2=C1C=C(C(=C2)Cl)Cl)C[C@H]1NCCC[C@@H]1O NAUDZBJMEJVRAJ-ZBFHGGJFSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- OBTFJECZUBGAPF-UXQCFNEQSA-N Cl.O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2c(Cl)ncnc12 Chemical compound Cl.O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2c(Cl)ncnc12 OBTFJECZUBGAPF-UXQCFNEQSA-N 0.000 claims 1
- AKLXHCCDMISWSK-GGMFNZDASA-N Cl.O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(ncc12)C(O)=O Chemical compound Cl.O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(ncc12)C(O)=O AKLXHCCDMISWSK-GGMFNZDASA-N 0.000 claims 1
- QGJXLDZCSUOUAE-HIFRSBDPSA-N ClC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C Chemical compound ClC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C QGJXLDZCSUOUAE-HIFRSBDPSA-N 0.000 claims 1
- BVKSNRSMQUASIT-ICSQTIAXSA-N ClC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)C Chemical compound ClC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1)C BVKSNRSMQUASIT-ICSQTIAXSA-N 0.000 claims 1
- XWWOKTAKYKWDMZ-YPMHNXCESA-N ClC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)Cl Chemical compound ClC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)Cl XWWOKTAKYKWDMZ-YPMHNXCESA-N 0.000 claims 1
- VLKMFLDCHBCQLL-YPMHNXCESA-N ClC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)F Chemical compound ClC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)F VLKMFLDCHBCQLL-YPMHNXCESA-N 0.000 claims 1
- NHLLAWQSYROECO-WPLSFSDESA-N ClC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)O)Cl Chemical compound ClC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)O)Cl NHLLAWQSYROECO-WPLSFSDESA-N 0.000 claims 1
- AYEHMNUMPJYPNX-MNOVXSKESA-N ClC1=CC(=C2C(=N1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)=O)Cl Chemical compound ClC1=CC(=C2C(=N1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)=O)Cl AYEHMNUMPJYPNX-MNOVXSKESA-N 0.000 claims 1
- SPOPDQBWAPNDHN-MFKMUULPSA-N ClC1=CC2=C(C=N1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound ClC1=CC2=C(C=N1)N=CN2CC(C[C@H]1NCCC[C@@H]1O)=O SPOPDQBWAPNDHN-MFKMUULPSA-N 0.000 claims 1
- NHGLDUIQZVQXQP-ZBFHGGJFSA-N ClC1=CC2=C(N(C(=N2)C)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl Chemical compound ClC1=CC2=C(N(C(=N2)C)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl NHGLDUIQZVQXQP-ZBFHGGJFSA-N 0.000 claims 1
- ATSFBLYQFPAOES-ZBFHGGJFSA-N ClC1=CC2=C(N(C(=N2)CC)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl Chemical compound ClC1=CC2=C(N(C(=N2)CC)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl ATSFBLYQFPAOES-ZBFHGGJFSA-N 0.000 claims 1
- BNVGISIVKYLMNQ-WBVHZDCISA-N ClC1=CC2=C(N(C(=N2)CN(C)C)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl Chemical compound ClC1=CC2=C(N(C(=N2)CN(C)C)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl BNVGISIVKYLMNQ-WBVHZDCISA-N 0.000 claims 1
- MANQQNJCRWOPFP-RJGUCTMASA-N ClC1=CC2=C(N(C(=N2)CO)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1Cl Chemical compound ClC1=CC2=C(N(C(=N2)CO)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1Cl MANQQNJCRWOPFP-RJGUCTMASA-N 0.000 claims 1
- CVZYSSQZBAPTOE-VIFPVBQESA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC2)=O)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC2)=O)C=C1Cl CVZYSSQZBAPTOE-VIFPVBQESA-N 0.000 claims 1
- FANIUVKCJPZLBU-YISXUXMPSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)(C)O)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)(C)O)C=C1Cl FANIUVKCJPZLBU-YISXUXMPSA-N 0.000 claims 1
- OJTVWEQASJIJJF-OCCSQVGLSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)(F)F)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)(F)F)C=C1Cl OJTVWEQASJIJJF-OCCSQVGLSA-N 0.000 claims 1
- ADSIANLUTJHONZ-HIFRSBDPSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=NO)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=NO)C=C1Cl ADSIANLUTJHONZ-HIFRSBDPSA-N 0.000 claims 1
- YEXHQCQFINNPOU-HIFRSBDPSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1 Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1 YEXHQCQFINNPOU-HIFRSBDPSA-N 0.000 claims 1
- HFHBNXLRAIHNIT-HIFRSBDPSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1Cl HFHBNXLRAIHNIT-HIFRSBDPSA-N 0.000 claims 1
- MJENTCDRVAVDCJ-RJGUCTMASA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)F)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)F)C=C1Cl MJENTCDRVAVDCJ-RJGUCTMASA-N 0.000 claims 1
- GCVVMSCOGHKDIY-OWJAWUPLSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)NC)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)NC)C=C1Cl GCVVMSCOGHKDIY-OWJAWUPLSA-N 0.000 claims 1
- KPJRXBAYZHBASI-RJGUCTMASA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)O)C=C1Cl KPJRXBAYZHBASI-RJGUCTMASA-N 0.000 claims 1
- APAAVHRQMDSSDW-OWJAWUPLSA-N ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)OC)C=C1Cl Chemical compound ClC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)OC)C=C1Cl APAAVHRQMDSSDW-OWJAWUPLSA-N 0.000 claims 1
- GUCBUGQUORCFTP-SOYIIFOFSA-N ClC=1C(=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)O)C Chemical compound ClC=1C(=C2C(=NC=1)N(C=N2)CC(C[C@H]1NCCC[C@@H]1O)O)C GUCBUGQUORCFTP-SOYIIFOFSA-N 0.000 claims 1
- GCIZJXRFTRIIRK-HIFRSBDPSA-N ClC=1C=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1)C Chemical compound ClC=1C=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1)C GCIZJXRFTRIIRK-HIFRSBDPSA-N 0.000 claims 1
- VWSBDQMFYJKMQI-KGLIPLIRSA-N ClC=1C=C2C(=NC=1)N(C=C2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound ClC=1C=C2C(=NC=1)N(C=C2)CC(C[C@H]1NCCC[C@@H]1O)=O VWSBDQMFYJKMQI-KGLIPLIRSA-N 0.000 claims 1
- CLIKEQFOMZCCPP-OLZOCXBDSA-N ClC=1C=C2C(=NC=1)N(N=C2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound ClC=1C=C2C(=NC=1)N(N=C2)CC(C[C@H]1NCCC[C@@H]1O)=O CLIKEQFOMZCCPP-OLZOCXBDSA-N 0.000 claims 1
- YABYUDNQQVLTMB-HIFRSBDPSA-N ClC=1C=C2C=NN(C2=CC=1)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound ClC=1C=C2C=NN(C2=CC=1)CC(C[C@H]1NCCC[C@@H]1O)=O YABYUDNQQVLTMB-HIFRSBDPSA-N 0.000 claims 1
- UNDXOXGDSUAJIC-HIFRSBDPSA-N ClC=1C=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1 Chemical compound ClC=1C=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1 UNDXOXGDSUAJIC-HIFRSBDPSA-N 0.000 claims 1
- WJTVVDRYDSWMFP-CABCVRRESA-N ClC=1C=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1C Chemical compound ClC=1C=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=1C WJTVVDRYDSWMFP-CABCVRRESA-N 0.000 claims 1
- ORQYGNKLLYAXSL-OLZOCXBDSA-N ClC=1N=CC=C2C=1N(C=C2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound ClC=1N=CC=C2C=1N(C=C2)CC(C[C@H]1NCCC[C@@H]1O)=O ORQYGNKLLYAXSL-OLZOCXBDSA-N 0.000 claims 1
- ZLRJOSBQHOLUEI-HIFRSBDPSA-N FC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C Chemical compound FC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C ZLRJOSBQHOLUEI-HIFRSBDPSA-N 0.000 claims 1
- CKFUYSKWBGZNDZ-YPMHNXCESA-N FC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C(F)(F)F Chemical compound FC1=C(C2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1)C(F)(F)F CKFUYSKWBGZNDZ-YPMHNXCESA-N 0.000 claims 1
- LAOSIPGVINMFRX-OCCSQVGLSA-N FC1=C(C=CC=2N(C(=NC=21)C)CC(C[C@H]1NCCC[C@@H]1O)=O)F Chemical compound FC1=C(C=CC=2N(C(=NC=21)C)CC(C[C@H]1NCCC[C@@H]1O)=O)F LAOSIPGVINMFRX-OCCSQVGLSA-N 0.000 claims 1
- RBKCOTCZUMFCLL-YPMHNXCESA-N FC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)F Chemical compound FC1=C(C=CC=2N(C=NC=21)CC(C[C@H]1NCCC[C@@H]1O)=O)F RBKCOTCZUMFCLL-YPMHNXCESA-N 0.000 claims 1
- YHFWYUKLAGHXBK-HIFRSBDPSA-N FC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1F Chemical compound FC1=CC2=C(N(C=N2)CC(C[C@H]2NCCC[C@@H]2O)=O)C=C1F YHFWYUKLAGHXBK-HIFRSBDPSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims 1
- BNKGCHYTBIQRLI-YISXUXMPSA-N N1(C=NC2=C1C=CC=C2)CC(C[C@H]1NCCC[C@@H]1O)(C)O Chemical compound N1(C=NC2=C1C=CC=C2)CC(C[C@H]1NCCC[C@@H]1O)(C)O BNKGCHYTBIQRLI-YISXUXMPSA-N 0.000 claims 1
- RGFDZDCHWHVFQQ-HIFRSBDPSA-N N1(C=NC2=C1C=CC=C2)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound N1(C=NC2=C1C=CC=C2)CC(C[C@H]1NCCC[C@@H]1O)=O RGFDZDCHWHVFQQ-HIFRSBDPSA-N 0.000 claims 1
- CTHXMTCOUMDMQD-ICSQTIAXSA-N N1(C=NC2=C1C=CC=C2)CC(C[C@H]1NCCC[C@@H]1O)O Chemical compound N1(C=NC2=C1C=CC=C2)CC(C[C@H]1NCCC[C@@H]1O)O CTHXMTCOUMDMQD-ICSQTIAXSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- RZLCWVQNCVMULI-HIFRSBDPSA-N OCC1=NC2=C(N1CC(C[C@H]1NCCC[C@@H]1O)=O)C=CC=C2 Chemical compound OCC1=NC2=C(N1CC(C[C@H]1NCCC[C@@H]1O)=O)C=CC=C2 RZLCWVQNCVMULI-HIFRSBDPSA-N 0.000 claims 1
- XISJOBLBMUQIIA-YPMHNXCESA-N OCC=1N(C=2C(=NC=CC=2)N=1)CC(C[C@H]1NCCC[C@@H]1O)=O Chemical compound OCC=1N(C=2C(=NC=CC=2)N=1)CC(C[C@H]1NCCC[C@@H]1O)=O XISJOBLBMUQIIA-YPMHNXCESA-N 0.000 claims 1
- YVVHDRTUFPRTQQ-OCCSQVGLSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C(=NC2=NC=CC=C21)C)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C(=NC2=NC=CC=C21)C)=O YVVHDRTUFPRTQQ-OCCSQVGLSA-N 0.000 claims 1
- YJYBOYYFJJSBDH-CVEARBPZSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=CC=2C1=NC=C(C=2C)C#N)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=CC=2C1=NC=C(C=2C)C#N)=O YJYBOYYFJJSBDH-CVEARBPZSA-N 0.000 claims 1
- FNAJFJHQBKIEEF-KGLIPLIRSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1C(=CC=C2)C(F)(F)F)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1C(=CC=C2)C(F)(F)F)=O FNAJFJHQBKIEEF-KGLIPLIRSA-N 0.000 claims 1
- SOLWVSFWYBCJBV-HIFRSBDPSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1C=C(C=C2)C(F)(F)F)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1C=C(C=C2)C(F)(F)F)=O SOLWVSFWYBCJBV-HIFRSBDPSA-N 0.000 claims 1
- ZSFTXFRQLFHWKQ-HIFRSBDPSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1C=CC(=C2)C(F)(F)F)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1C=CC(=C2)C(F)(F)F)=O ZSFTXFRQLFHWKQ-HIFRSBDPSA-N 0.000 claims 1
- LIXYPXFVJJQSCA-HIFRSBDPSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1CCCC2)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=C1CCCC2)=O LIXYPXFVJJQSCA-HIFRSBDPSA-N 0.000 claims 1
- KKYCDDCXOCWVKO-PWSUYJOCSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=NC(=CC=C21)C(F)(F)F)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC2=NC(=CC=C21)C(F)(F)F)=O KKYCDDCXOCWVKO-PWSUYJOCSA-N 0.000 claims 1
- HKRSYHVYVJXFGI-NEPJUHHUSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC=2C1=NC(=CC=2)C(F)(F)F)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC=2C1=NC(=CC=2)C(F)(F)F)=O HKRSYHVYVJXFGI-NEPJUHHUSA-N 0.000 claims 1
- XRBSJNJDLNBAQP-OCCSQVGLSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC=2C1=NC=C(C=2)C#N)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC=2C1=NC=C(C=2)C#N)=O XRBSJNJDLNBAQP-OCCSQVGLSA-N 0.000 claims 1
- PQSCSZCAQJJNLB-OLZOCXBDSA-N O[C@@H]1[C@H](NCCC1)CC(CN1C=NC=2C1=NC=CC=2)=O Chemical compound O[C@@H]1[C@H](NCCC1)CC(CN1C=NC=2C1=NC=CC=2)=O PQSCSZCAQJJNLB-OLZOCXBDSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- CPZBTYRIGVOOMI-UHFFFAOYSA-N methylsulfanyl(methylsulfanylmethoxy)methane Chemical compound CSCOCSC CPZBTYRIGVOOMI-UHFFFAOYSA-N 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (17)
1. Spoj predstavljen sljedećom kemijskom formulom 1, ili farmaceutski prihvatljiva sol istog:
[image]
u kemijskoj formuli 1,
n je 1, ili 2,
R1 je vodik, ili hidroksi,
R1' je vodik,
R2 je hidroksi, halogen, amino, C1-4 alkilamino, di(C1-4 alkil)amino ili C1-4 alkoksi; R3 je vodik, halogen, C1-4 alkil, ili C1-4 haloalkil; ili R2 i R3 zajedno formiraju okso (=O), hidroksiimino (=N-OH), ili C1-4 alkoksiimino (=N-O-(C1-4 alkil));
Y je
[image]
Y1 je N, CH, ili CR4,
gdje R4 je C1-4 alkil, C1-4 hidroksialkil, C1-4 alkil supstituiran sa C1-4 alkoksi, C1-4 haloalkil, ili -(CH2)mNR9R10, gdje m je cijeli broj od 1 do 4, i R9 i R10 su svako nezavisno vodik, ili C1-4 alkil,
Y2 je N, ili CH,
A je benzen, heteroaril koji ima 1 do 4 atoma dušika, ili cikloheksen, kao šestočlani prsten,
k je cijeli broj od 0 do 4, i
svako od Ra je nezavisno C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, halogen, cijano, ili karboksi.
2. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje R2 je hidroksi, fluoro, amino, metilamino, dimetilamino ili metoksi; R3 je vodik, fluoro, metil, ili trifluorometil; ili R2 i R3 zajedno formiraju okso (=O), hidroksiimino (=N-OH), ili metoksiimino (=N-OCH3).
3. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje A je benzen, piridin, pirimidin, ili cikloheksen.
4. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje R4 je metil, etil, hidroksimetil, hidroksietil, 1-hidroksietil, trifluorometil, metoksimetil, aminometil, ili (dimetilamino)metil.
5. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje
Y je
[image]
Y3 je N, ili C-R5;
Y4 je N, ili C-R6;
Y5 je N, ili C-R7;
Y6 je N, ili C-R8,
R5 je vodik, C1-4 alkil, C1-4 haloalkil, ili halogen;
R6 je vodik, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, halogen, cijano, ili karboksi;
R7 je vodik, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, halogen, ili cijano; i
R8 je vodik, C1-4 alkil, C1-4 haloalkil, C1-4 haloalkoksi, ili halogen.
6. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 5,
gdje
R5 je vodik, metil, trifluorometil, fluoro, kloro, ili bromo;
R6 je vodik, metil, trifluorometil, trifluorometoksi, fluoro, kloro, bromo, cijano, ili karboksi;
R7 je vodik, metil, trifluorometil, fluoro, kloro, ili bromo; i
R8 je vodik, metil, trifluorometil, trifluorometoksi, kloro, ili bromo.
7. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje
Y je
[image]
[image]
ili
[image]
i
k je cijeli broj od 0 do 2.
8. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 7,
gdje svako od Ra je nezavisno C1-4 alkil, C1-4 haloalkil, C1-4 haloalkoksi, halogen, cijano, ili karboksi.
9. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 8,
gdje svako od Ra je nezavisno metil, trifluorometil, trifluorometoksi, fluoro, kloro, bromo, cijano, ili karboksi.
10. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje
n je cijeli broj od 1 ili 2,
R1 je vodik ili hidroksi,
R1' je vodik,
R2 je hidroksi, halogen, C1-4 alkilamino, ili C1-4 alkoksi;
R3 je vodik, halogen, C1-4 alkil, ili C1-4 haloalkil; ili R2 i R3 zajedno formiraju okso (=O), hidroksiimino(=N-OH), ili C1-4 alkoksiimino (=N-O-(C1-4 alkil));
Y je
[image]
Y1 je CH, ili CR4,
gdje R4 je C1-4 alkil, C1-4 hidroksialkil, C1-4 alkil supstituiran sa C1-4 alkoksi, C1-4 haloalkil, C1-4 alkil supstituiran sa amino, ili C1-4 alkil supstituiran sa di(C1-4 alkil)amino,
Y2 je N,
k je cijeli broj od 0 do 2, i
svako od Ra je nezavisno C1-4 alkil, C1-4 haloalkil, C1-4 haloalkoksi, ili halogen.
11. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje
n je 2,
R1 je hidroksi,
R1' je vodik,
R2 je hidroksi; R3 je vodik; ili R2 i R3 zajedno formiraju okso (=O);
Y je
[image]
Y1 je CH,
Y2 je N,
k je cijeli broj od 0 do 2,
svako od Ra je nezavisno C1-4 alkil, C1-4 haloalkil, halogen, ili cijano.
12. Spoj ili farmaceutski prihvatljiva sol istog u skladu sa patentnim zahtjevom 1,
gdje spoj predstavljen kemijskom formulom 1 je bilo koje odabrano iz grupe koja se sastoji od:
1) 1-(1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
2) 1-(5-kloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
3) 1-(6-kloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
4) 1-(5-bromo-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
5) 1-(6-bromo-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
6) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(5-(trifluorometil)-1H-benzo[d]imidazol-1-il)propan-2-on,
7) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(6-(trifluorometil)-1H-benzo[d]imidazol-1-il)propan-2-on,
8) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(7-(trifluorometil)-1 H-benzo[d]imidazol-1-il)propan-2-on,
9) 1-(5,6-dimetil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
10) 1-(5,6-difluoro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
11) 1-(4,5-difluoro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
12) 1-(4,5-dikloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
13) 1-(5-fluoro-4-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
14) 1-(5-kloro-4-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
15) 1-(5-bromo-4-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
16) 1-(4,5-dimetil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
17) 1-(5-fluoro-4-(trifluorometil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
18) 1-(5-bromo-4-(trifluorometil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
19) 1-(4-bromo-5-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
20) 1-(5-bromo-4-fluoro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
21) 1-(4-kloro-5-fluoro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
22) 1-(5-bromo-4-kloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
23) 1-(6-bromo-4-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
24) 1-(6-kloro-4-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
25) 1-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
26) 1-(6-bromo-5-fluoro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
27) 1-(5,6-dibromo-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
28) 1-(6-kloro-7-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
29) 1-(5-bromo-1H-imidazo[4,5-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
30) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(5-(trifluorometil)-1H-imidazo[4,5-b]piridin-1-il)propan-2-on,
31) 1-(6-bromo-1H-imidazo[4,5-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
32) 1-(6-kloro-1H-imidazo[4,5-c]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
33) 1-(7-bromo-1H-imidazo[4,5-c]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
34) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(3H-imidazo[4,5-b]piridin-3-il)propan-2-on,
35) 1-(5-bromo-3H-imidazo[4,5-b]piridin-3-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
36) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(5-(trifluorometil)-3H-imidazo[4,5-b]piridin-3-il)propan-2-on,
37) 1-(6-bromo-3H-imidazo[4,5-b]piridin-3-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
38) 3-(3-((2R,3S)-3-hidroksipiperidin-2-il)-2-oksopropil)-3H-imidazo[4,5-b]piridin-6-karbonitril,
39) 1-(6-kloro-7-metil-3H-imidazo[4,5-b]piridin-3-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
40) 1-(6-bromo-7-metil-3H-imidazo[4,5-b]piridin-3-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
41) 1-(5,7-dikloro-3H-imidazo[4,5-b]piridin-3-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
42) 1-(6-bromo-7-kloro-3H-imidazo[4,5-b]piridin-3-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
43) 3-(3-((2R,3S)-3-hidroksipiperidin-2-il)-2-oksopropil)-3H-imidazo[4,5-c]piridin-6-karboksilna kiselina hidroklorid sol,
44) 1-(6-kloro-9H-purin-9-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on hidroklorid sol,
45) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(4,5,6,7-tetrahidro-1H-benzo[d]imidazol-1-il)propan-2-on,
46) 1-(5,6-dikloro-2-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
47) 1-(4,5-difluoro-2-metil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
48) 1-(5,6-dikloro-2-etil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
49) 1-((2R,3S)-3-hidroksipiperidin-2-il)-3-(2-metil-1H-imidazo[4,5-b]piridin-1-il)propan-2-on,
50) 1-(5,6-dikloro-2-(trifluorometil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
51) 1-(5,6-dikloro-2-((dimetilamino)metil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
52) 1-(2-(aminometil)-5,6-dikloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
53) 1-(6-fluoro-2-(2-hidroksietil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
54) 1-(2-((R)-1-hidroksietil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
55) 1-(2-((S)-1-hidroksietil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
56) 1-(2-(hidroksimetil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
57) 1-(5-bromo-2-(hidroksimetil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
58) 1-(6-bromo-2-(hidroksimetil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
59) 1-(2-(hidroksimetil)-6-(trifluorometil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
60) 1-(2-(hidroksimetil)-5-(trifluorometoksi)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
61) 1-(2-(hidroksimetil)-7-(trifluorometoksi)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
62) 1-(2-(hidroksimetil)-4,5-dimetil-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
63) 1-(5,6-dikloro-2-(metoksimetil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
64) 1-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on oksim,
65) 1-(5,6-dikloro-2-(hidroksimetil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on oksim,
66) 1-(6-bromo-1H-imidazo[4,5-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on oksim,
67) 1-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on O-metil oksim,
68) 1-(2-(hidroksimetil)-1H-imidazo[4,5-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
69) (2R,3S)-2-(3-(1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
70) (2R,3S)-2-(3-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
71) (2R,3S)-2-(3-(5-bromo-4-kloro-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
72) (2R,3S)-2-(3-(5-bromo-4-(trifluorometil)-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
73) (2R,3S)-2-(3-(4-bromo-5-metil-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
74) (2R,3S)-2-(3-(5-bromo-4-fluoro-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
75) (2R,3S)-2-(3-(4,5-dikloro-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
76) (2R,3S)-2-(3-(5-kloro-4-metil-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
77) (2R,3S)-2-(3-(6-kloro-7-metil-3H-imidazo[4,5-b]piridin-3-il)-2-hidroksipropil)piperidin-3-ol,
78) (2R,3S)-2-(3-(6-bromo-7-metil-3H-imidazo[4,5-b]piridin-3-il)-2-hidroksipropil)piperidin-3-ol,
79) (2R,3S)-2-(3-(6-bromo-7-kloro-3H-imidazo[4,5-b]piridin-3-il)-2-hidroksipropil)piperidin-3-ol,
80) (2R,3S)-2-(3-(1H-benzo[d]imidazol-1-il)-2-hidroksi-2-metilpropil)piperidin-3-ol,
81) (2R,3S)-2-(3-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-2-fluoropropil)piperidin-3-ol,
82) (2R,3S)-2-(3-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-2,2-difluoropropil)piperidin-3-ol,
83) (2R,3S)-2-(3-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-2-metoksipropil)piperidin-3-ol,
84) (2R,3S)-2-(3-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-2-hidroksi-2-metilpropil)piperidin-3-ol,
85) (2R,3S)-2-(2-((5-bromo-4-metil-1H-benzo[d]imidazol-1-il)metil)-3,3,3-trifluoro-2-hidroksipropil)piperidin-3-ol,
86) (2R,3S)-2-(3-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-2-(metilamino)propil)piperidin-3-ol,
87) 1-(5,6-dikloro-2-(hidroksimetil)-1H-benzo[d]imidazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
88) (2R,3S)-2-(3-(5,6-dikloro-2-(hidroksimetil)-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
89) (2R,3S)-2-(3-(5-bromo-4-metil-1H-benzo[d]imidazol-1-il)-2-hidroksipropil)piperidin-3-ol,
90) (S)-1-(5,6-dikloro-1H-benzo[d]imidazol-1-il)-3-(pirolidin-2-il)propan-2-on,
91) 1-(5-kloro-1H-pirolo[2,3-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
92) 1-(6-bromo-1H-pirolo[2,3-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
93) 1-(7-kloro-1H-pirolo[2,3-c]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
94) 1-(6-bromo-1H-pirolo[3,2-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
95) 1-(3-((2R,3S)-3-hidroksipiperidin-2-il)-2-oksopropil)-4-metil-1H-pirolo[2,3-b]piridin-5-karbonitril,
96) 1-(5-kloro-1H-indazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
97) 1-(4-bromo-5-metil-1H-indazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
98) 1-(5-kloro-1H-pirazolo[3,4-b]piridin-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on,
99) 1-(5-kloro-1H-benzo[d][1,2,3]triazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on, i
100) 1-(6-kloro-1H-benzo[d][1,2,3]triazol-1-il)-3-((2R,3S)-3-hidroksipiperidin-2-il)propan-2-on.
13. Metoda za pripremanje spoja predstavljenog sljedećom kemijskom formulom 1 iz patentnog zahtjeva 1, koja obuhvaća korake:
1) reagiranja spoja predstavljenog sljedećom kemijskom formulom 1-1 sa spojem predstavljenim sljedećom kemijskom formulom 1-2 da se pripremi spoj predstavljen sljedećom kemijskom formulom 1-3; i
2) podvrgavanja spoja predstavljenog sljedećom kemijskom formulom 1-3 reakciji uklanjanja zaštite da se pripremi spoj predstavljen sljedećom kemijskom formulom 1:
[image]
[image]
[image]
[image]
[image]
U kemijskim formulama 1, 1-1, 1-2 i 1-3,
n, R1, R1', R2, R3, Y1, Y2, A, k i Ra su kao što je definirano u patentnom zahtjevu 1,
X je halogen,
P1 je bilo koja zaštitna grupa izabrana iz grupe koja se sastoji od karbobenziloksi, para-metoksibenzil karbonil, terc-butiloksikarbonil, 9-fluorenil metiloksi karbonil, acetil, benzoil, benzil i para-metoksibenzil,
P2 je bilo koja zaštitna grupa izabrana iz grupe koja se sastoji od acetil, benzoil, benzil, beta-metoksietoksi metil eter, metoksimetil eter, para-metoksibenzil eter, metiltiometil eter, pivaloil, tetrahidropiranil, tritil, terc-butildimetilsilil, triizopropilsilil eter, i etoksietil eter,
pod uvjetom da kada R1 je vodik, vodik je supstituiran umjesto O-P2 u kemijskim formulama 1-1 i 1-3.
14. Farmaceutska kompozicija za primjenu u prevenciji ili liječenju raka, inflamatornih bolesti, autoimunih bolesti ili fibroze, koja sadrži spoj iz bilo kojeg od patentnih zahtjeva 1 do 12, ili farmaceutski prihvatljivu sol istog.
15. Spoj predstavljen kemijskom formulom 2-9 ili spoj predstavljen kemijskom formulom 2-13.
[image]
[image]
u kemijskim formulama 2-9 i 2-13,
P1 i P2 su svako nezavisno zaštitna grupa,
n je 1 ili 2,
R1' je vodik,
R4 je C1-4 alkil, C1-4 hidroksialkil, C1-4 alkil supstituiran sa C1-4 alkoksi, C1-4 haloalkil, ili -(CH2)mNR9R10, gdje m je cijeli broj od 1 do 4, R9 i R10 su svako nezavisno vodik ili C1-4 alkil,
A je benzen, heteroaril koji ima 1 do 4 atoma dušika, ili cikloheksen, kao šestočlani prsten,
k je cijeli broj od 0 do 4,
svako od Ra je nezavisno C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 haloalkoksi, halogen, cijano, ili karboksi.
16. Metoda za pripremanje spoja predstavljenog sljedećom kemijskom formulom 2-9 iz patentnog zahtjeva 15, koja obuhvaća korake:
1) reagiranja spoja predstavljenog sljedećom kemijskom formulom 2-5 sa spojem predstavljenim sljedećom kemijskom formulom 2-6 u prisustvu baze da se pripremi spoj predstavljen sljedećom kemijskom formulom 2-7;
2) reagiranja spoja predstavljenog kemijskom formulom 2-7 u prisustvu vodika i metala da se pripremi spoj predstavljen sljedećom kemijskom formulom 2-8; i
3) reagiranja spoja predstavljenog sljedećom kemijskom formulom 2-8 i) u prisustvu trimetil ortoformata ili trietil ortoformata, i para toluensulfonske kiseline ili piridinij para toluensulfonata, ili ii) u prisustvu mravlje kiseline, da se pripremi spoj predstavljen sljedećom kemijskom formulom 2-9:
[image]
[image]
[image]
[image]
[image]
u kemijskim formulama 2-5 do 2-9,
P1, P2, n, R1', A, k i Ra su kao što je definirano u patentnom zahtjevu 15.
17. Metoda za pripremanje spoja predstavljenog sljedećom kemijskom formulom 2-13 iz patentnog zahtjeva 15, koja obuhvaća korake:
1) reagiranja spoja predstavljenog sljedećom kemijskom formulom 2-5 sa spojem predstavljenim sljedećom kemijskom formulom 2-6 u prisustvu baze da se pripremi spoj predstavljen sljedećom kemijskom formulom 2-7;
2) reagiranja spoja predstavljenog sljedećom kemijskom formulom 2-7 u prisustvu vodika i metala da se pripremi spoj predstavljen sljedećom kemijskom formulom 2-8;
3) reagiranja spoja predstavljenog kemijskom formulom 2-8 i R4-supstituisane karboksilne kiseline (R4-COOH) u prisustvu amid spajajućeg reagensa od bis-(2-okso-3-oksazolidinil)fosforil hidroklorida, 1-etil-(3-(3-dimetilamino)propil)-karbodiimid hidroklorida, benzotriazol-1-iloksi-tris-(pirolidino)fosfonij heksafluorofosfata, benzotriazol-ola, (benzotriazol-1-iloksi) tris(dimetilamino)fosfonij heksafluorofosfata ili O-(benzotriazol-1-il)-N,N,N,N'-tetrametiluronij heksafluorofosfata, i baze od trietilamina, diizopropil etilamina, piridina, dimetilanilina, dimetilaminopiridina ili natrij hidroksida da se pripremi spoj predstavljen kemijskom formulom 2-12; i
4) reagiranja spoja predstavljenog kemijskom formulom 2-12 i) u prisustvu trimetil ortoformata ili trietil ortoformata, i paratoluensulfonske kiseline ili piridinij para toluensulfonata, ili ii) u prisustvu mravlje kiseline da se pripremi spoj predstavljen kemijskom formulom 2-13;
[image]
[image]
[image]
[image]
[image]
[image]
[image]
U kemijskim formulama 2-5 do 2-8, 2-12 i 2-13,
P1, P2, n, R1', R4, A, k i Ra su kao što je definirano u patentnom zahtjevu 15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140076674 | 2014-06-23 | ||
PCT/KR2015/006377 WO2015199418A2 (ko) | 2014-06-23 | 2015-06-23 | 신규한 헤테로고리 화합물 |
EP15812382.8A EP3159335B1 (en) | 2014-06-23 | 2015-06-23 | Novel heterocyclic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200785T1 true HRP20200785T1 (hr) | 2020-08-07 |
Family
ID=54938901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200785TT HRP20200785T1 (hr) | 2014-06-23 | 2020-05-13 | Novi heterociklični spoj |
Country Status (18)
Country | Link |
---|---|
US (1) | US10081634B2 (hr) |
EP (1) | EP3159335B1 (hr) |
JP (1) | JP6272510B2 (hr) |
KR (1) | KR102276340B1 (hr) |
CN (1) | CN106458923B (hr) |
AU (1) | AU2015280874B2 (hr) |
CA (1) | CA2951798C (hr) |
ES (1) | ES2795368T3 (hr) |
HR (1) | HRP20200785T1 (hr) |
HU (1) | HUE049482T2 (hr) |
MY (1) | MY174343A (hr) |
NZ (1) | NZ727715A (hr) |
PH (1) | PH12016502568A1 (hr) |
PL (1) | PL3159335T3 (hr) |
PT (1) | PT3159335T (hr) |
RS (1) | RS60264B1 (hr) |
SI (1) | SI3159335T1 (hr) |
WO (1) | WO2015199418A2 (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
JP2019196308A (ja) * | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
AR110963A1 (es) | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
WO2024080777A1 (ko) * | 2022-10-12 | 2024-04-18 | 주식회사 대웅제약 | 신장염의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102177152A (zh) * | 2008-08-11 | 2011-09-07 | 哈佛大学校长及研究员协会 | 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途 |
WO2010096170A2 (en) * | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
WO2013106702A1 (en) * | 2012-01-13 | 2013-07-18 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
KR102277538B1 (ko) | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
-
2015
- 2015-06-23 CA CA2951798A patent/CA2951798C/en active Active
- 2015-06-23 KR KR1020150088872A patent/KR102276340B1/ko active IP Right Grant
- 2015-06-23 PT PT158123828T patent/PT3159335T/pt unknown
- 2015-06-23 NZ NZ727715A patent/NZ727715A/en unknown
- 2015-06-23 SI SI201531212T patent/SI3159335T1/sl unknown
- 2015-06-23 CN CN201580029527.XA patent/CN106458923B/zh active Active
- 2015-06-23 EP EP15812382.8A patent/EP3159335B1/en active Active
- 2015-06-23 JP JP2016571347A patent/JP6272510B2/ja active Active
- 2015-06-23 MY MYPI2016704579A patent/MY174343A/en unknown
- 2015-06-23 WO PCT/KR2015/006377 patent/WO2015199418A2/ko active Application Filing
- 2015-06-23 RS RS20200562A patent/RS60264B1/sr unknown
- 2015-06-23 PL PL15812382T patent/PL3159335T3/pl unknown
- 2015-06-23 US US15/312,192 patent/US10081634B2/en active Active
- 2015-06-23 ES ES15812382T patent/ES2795368T3/es active Active
- 2015-06-23 AU AU2015280874A patent/AU2015280874B2/en active Active
- 2015-06-23 HU HUE15812382A patent/HUE049482T2/hu unknown
-
2016
- 2016-12-21 PH PH12016502568A patent/PH12016502568A1/en unknown
-
2020
- 2020-05-13 HR HRP20200785TT patent/HRP20200785T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US10081634B2 (en) | 2018-09-25 |
PH12016502568B1 (en) | 2017-04-17 |
ES2795368T3 (es) | 2020-11-23 |
AU2015280874B2 (en) | 2017-12-14 |
KR20150146462A (ko) | 2015-12-31 |
CA2951798A1 (en) | 2015-12-30 |
EP3159335A4 (en) | 2017-11-15 |
KR102276340B1 (ko) | 2021-07-12 |
PH12016502568A1 (en) | 2017-04-17 |
WO2015199418A3 (ko) | 2016-04-14 |
CN106458923B (zh) | 2019-09-10 |
EP3159335B1 (en) | 2020-04-29 |
PL3159335T3 (pl) | 2020-10-05 |
CA2951798C (en) | 2018-07-24 |
MY174343A (en) | 2020-04-09 |
RS60264B1 (sr) | 2020-06-30 |
WO2015199418A2 (ko) | 2015-12-30 |
CN106458923A (zh) | 2017-02-22 |
AU2015280874A1 (en) | 2017-01-12 |
US20170088551A1 (en) | 2017-03-30 |
JP6272510B2 (ja) | 2018-01-31 |
HUE049482T2 (hu) | 2020-09-28 |
EP3159335A2 (en) | 2017-04-26 |
NZ727715A (en) | 2017-09-29 |
JP2017520539A (ja) | 2017-07-27 |
PT3159335T (pt) | 2020-06-05 |
SI3159335T1 (sl) | 2020-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200785T1 (hr) | Novi heterociklični spoj | |
AU2017221865B2 (en) | Viral replication inhibitors | |
AU2009278442B2 (en) | Imidazopyridin-2-one Derivatives | |
KR101130928B1 (ko) | 치환된 이미다조 고리 시스템 및 방법 | |
AU2009266090B2 (en) | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | |
HRP20170349T1 (hr) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
HRP20171752T1 (hr) | Novi derivati indolizina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
HRP20211483T1 (hr) | Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka | |
RS54586B1 (en) | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | |
HRP20200104T1 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
RS54833B1 (sr) | Novi hiralni n-acil-5,6,7, (8-supstituisan)-tetrahidro-[1,2,4]triazolo [4,3-a]pirazini kao selektivni antagonisti nk-3 receptora, farmaceutsko jedinjenje, i postupci za upotrebu u nk-3 receptorom posredovanim poremećajima | |
JP2020527174A5 (hr) | ||
HRP20140632T1 (hr) | Derivati 2-arimidazola kao inhibitori pde10a enzima | |
HRP20020547A2 (hr) | Azaindoles | |
HRP20131210T1 (hr) | Heteroaromatski aril triazol derivati kao inhibitori pde10a enzima | |
JP2013512953A5 (hr) | ||
EP1660475A1 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
WO2013042035A4 (en) | Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections | |
US7279575B2 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
RU2005138546A (ru) | 2-имидазобензотиазолы, как лиганды аденозинового рецептора | |
KR102103188B1 (ko) | 케모카인 수용체의 길항제 | |
JP2016517877A5 (hr) | ||
CA2579083A1 (en) | Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof | |
JP2022530988A (ja) | Trex1のモジュレーター | |
NZ716783A (en) | Inhibitors of influenza viruses replication |